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Edited by Felix WielandAbstract The human prostaglandin EP3 receptor comprises
eight isoforms that diﬀer in carboxyl-tail. We show here that the
isoforms are traﬃcked diﬀerently. When expressed in HEK293
cells, the isoforms located to the cell surface, although a fraction
of some remained in the cell. Upon prostaglandin E2 stimulation,
EP3.I internalized almost completely, EP3.II, EP3.V, EP3.VI
and EP3.f internalized to a lesser extent and EP3.III and
EP3.IV did not internalize. Both EP3.I and EP3.f internalized
with b-arrestin and internalization were blocked by a dominant
negative form of Eps15, a clathrin-associated protein. Although
EP3.II internalized, b-arrestin did not translocate with the
receptor and internalization was not blocked by mutant Eps15.
EP3.V and EP3.VI internalized to discrete areas of the cell with
b-arrestin.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Endocytosis; Clathrin; Eps15EP3.I IRYHTNNYASSSTSLPCQCSSTLMWSDH-
LER
EP3.II VANAVSSCSNDGQKGQPISLSNEIIQTEA
EP3.III EEFWGN
EP3.IV MRKRRLREQEEFWGN
EP3.V MRKRRLREQEMGPDGRCFCHAWRQVP-
RTWCSSHDREPCSVQLS
EP3.VI EMGPDGRCFCHAWRQVPRTWCSSHDRE-
PCSVQLS
EP3.e MRKRRLREQLICSLRTLRYRGQLHIVGK-
YKPIVC
EP3.f MRKRRLREQAPLLPTPTVIDPSRFCAQPF-
RWFLDLSFPAMSSSHPQLPLTLASFKLLR-
EPCSVQLS1. Introduction
The G protein-coupled receptor (GPCR) superfamily con-
tains many receptor subtypes that are stimulated by the same
endogenous ligand. The subtypes often couple to diﬀerent G
proteins and have diﬀerent distribution patterns, allowing the
same ligand to exert multiple eﬀects. The GPCR superfamily is
further complicated by the existence of isoforms of a particular
subtype generated by alternative splicing. Splice variants for
over 30 GPCRs have been discovered, including those for the
thromboxane A2 [1], l opioid [2], serotonin 5HT4 [3] and
prostaglandin EP3 receptors [4], and a review of the literature
indicates that splice variants occur mainly at the carboxyl-
terminus.
In terms of molecular regulation, splice variants show dif-
ferences in desensitization and internalization. For example, a
splice variant of the turkey b1-adrenergic receptor, with an
additional 59 amino acids, is resistant to internalization com-
pared to its shorter counterpart [5]. The tachykinin NK1 re-
ceptor has a short variant that is resistant to internalization [6].
In the case of the metabotropic glutamate receptor, mGluR1,
the b isoform undergoes rapid constitutive internalization [7].* Corresponding author. Fax: +1-215-707-7068.
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doi:10.1016/j.febslet.2004.06.089Two C-tail splice variants of the thromboxane A2 receptor
(TP) display diﬀerences in traﬃcking [8]. TPb, the longer iso-
form, undergoes arrestin-dependent agonist-induced seques-
tration, while its shorter counterpart, TPa, does not,
suggesting that alternative splicing of the receptor is important
for regulation of arrestin binding and internalization. Al-
though some splice variants have increased numbers of serine
and threonine phosphorylation sites in their cytoplasmic tails,
this seems to have only modest eﬀects on desensitization and
internalization of the receptors [9].
Prostaglandin E2 (PGE2) exerts its actions through four
distinct GPCR subtypes, designated EP1, EP2, EP3 and EP4.
The EP1 receptor couples to phospholipase C, the EP2 and
EP4 receptors couple to stimulation of adenylyl cyclase, and
the EP3 receptor couples to inhibition of adenylyl cyclase.
The human EP3 receptor exists as eight isoforms that diﬀer in
carboxyl-tail region [4,10,11]. The isoforms may serve diﬀer-
ent functions and contribute to the diversity of the actions of
PGE2. The isoforms are identical over the ﬁrst 359 amino
acids up to the end of the seventh transmembrane helix, but
diﬀer in carboxyl-tail, which ranges in length from 6 to 66
amino acids.1.1. Carboxyl-terminal domains of isoforms of the human EP3
receptorWhen expressed in a variety of cells lines, the isoforms dis-
play similar aﬃnity for PGE2 but diﬀer in coupling to G
proteins and in other properties including constitutive activity
[12–14].
In this study, we examined agonist-induced internalization
of the isoforms. Our results indicate that the C-tail of theblished by Elsevier B.V. All rights reserved.
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induced internalization.Fig. 1. Western blot showing the speciﬁcity of the HA-antibody for the
EP3 HA-constructs. HEK293 cells stably expressing HA-tagged EP3
isoforms I, II, III, IV, V, VI, and f were grown to 75% conﬂuence and
lysed with SDS sample buﬀer. HEK293 cells transfected with vector
alone (mock transfected) were treated similarly. 30 lg samples were
resolved by SDS–PAGE and transferred to nitrocellulose membrane.
Membranes were probed with the HA.11 monoclonal antibody fol-
lowed by goat anti-mouse HRP-conjugated secondary antibody. An-
tibody labeling was detected by chemiluminescence. Each isoform was
detected at around 47 kDa, the calculated molecular weight of the
isoforms. Molecular mass is indicated on the left.2. Materials and methods
2.1. Materials
HAmonoclonal antibody (HA 11) was from Babco (Richmond, CA,
USA). Alexa 594 goat anti-mouse antibody was from Molecular
Probes (Eugene, OR, USA). HEK293 cells and Zeocin were from In-
vitrogen (Carlsbad, CA, USA). DMEM, Lipofectamine 2000, and
geneticin were from Gibco BRL (Grand Island, NY, USA). PGE2 was
from Biomol (Plymouth Meeting, PA, USA). The cDNA for GFP-
arrestin 2 was provided by Dr. Jeﬀrey Benovic (Thomas Jeﬀerson
University, Philadelphia, PA, USA). The cDNA for GFP-tagged
dominant negative Eps15 (ED95/295) was provided by Dr. Alexandre
Benmerah (Institut Cochin, Paris, France).
2.2. Cell-lines expressing the EP3 receptor isoforms
cDNAs for EP3 receptor isoforms I, II, III, IV, V, VI, e and f were
prepared by PCR from human uterus cDNA. Each isoform was epi-
tope-tagged with a hemagglutinin (HA) tag. A common forward pri-
mer incorporating an EcoRI restriction site and the HA tag, encoding
the amino acid sequence YPYDVPDYA following the N-terminal
methionine, was used to amplify each isoform. The sequence of the
forward primer was ATG GAA TTC AAC ATG TAC CCA TAC
GAC GTC CCA GAC TAC GCT AAG GAG ACC CGG GGC TAC
GGA, with the HA tag indicated in italics. The reverse primer for
EP3.I was AGT AAG CTT TCA TCT TTC CAA ATG GTC GCT
CCA. The reverse primer for EP3.II was AGT AAG CTT TCA TCA
TGC TTC TGT CTG TAT TAT TTC ATT. The reverse primer for
EP3.III was AGT AAG CTT TTA ATT TCC CCA AAA TTC CTC
CTG. The reverse primer for EP3.IV was TTA AAG CTT TTA ATT
TCC CCA AAA TTC CTC TTG CTC. The reverse primer for EP3.V,
VI, and f was TCA AAG CTT TCA GCT TAG CTG GAC ACT
GCA GGG TTC. The products were ligated into the expression vector
pcDNA3.1zeo()). Isoforms were sequenced and found to be identical
to those published [4,11], except for isoform e, which showed a single
base change coding for a diﬀerent carboxyl-tail from that published.
Our sequence is consistent with that from the human genome sequence
so that the original sequence may be in error. Because of the diﬀerence
in sequence, we did not study isoform e.
The isoforms were expressed in HEK293 cells cultured in Dulbecco’s
Modiﬁed Eagle’s Medium with 10% fetal calf serum. Cells were
transfected using Lipofectamine 2000 in a 6-well dish, according to the
manufacturer’s instructions. Stable cells were selected with zeocin and
single clones obtained by serial dilution.
The HA-tagged isoforms were also transiently expressed in HEK293
cells, together with GFP-labeled dominant negative mutant form of
Eps15, a clathrin binding protein previously shown to inhibit clathrin-
dependent endocytosis [15].
2.3. Immunoblot analysis
HEK293 cells stably expressing HA-tagged EP3 isoforms I, II, III,
IV, V, VI, and f were grown to75% conﬂuence and lysed with SDS
sample buﬀer containing 50 mM dithiothreitol. HEK293 cells trans-
fected with vector alone (mock transfected) were treated similarly.
Each sample was boiled for 5 min, centrifuged, and resolved by SDS–
PAGE. Each lane contained 30 lg of protein. Protein from the gels
were transferred to nitrocellulose membrane. Membranes was blocked
with 5% milk in TBST, probed with the HA.11 monoclonal antibody
at a 1:2000 dilution overnight at 4 C. After washing, the membranes
were incubated with an IgG goat anti-rabbit HRP-linked secondary
antibody (1:5000) for 1 h at room temperature. Blots were visualized
using enhanced chemiluminescence by use of Super Signal (Pierce,
Rockford, IL) and developed on X-ray ﬁlm.
2.4. Microscopy
HEK293 cells expressing HA-tagged EP3 isoforms were grown to
50% conﬂuence in 6-well plates on poly-L-lysine coated coverslips.
Cells were treated with anti-HA monoclonal antibody at a 1:500 di-
lution for 60 min at 25 C in DMEM with 1% BSA. Cells were washedand treated with or without PGE2 for 60 min. Cells were ﬁxed with 2%
paraformaldehyde (PFA), permeabilized with 0.01% Triton X-100 and
blocked with 5% non-fat dried milk in PBS at 37 C for 30 min. Cells
were incubated with goat anti-mouse Alexa-594-conjugated antibody
at a 1:150 dilution at 37 C for 30 min. Cells were washed and the
coverslips mounted on slides. Images were obtained using a Leica
TCS-NT confocal microscope.
For experiments using b-arrestin 2, HEK293 cells expressing the EP3
receptor were grown to conﬂuence in 6-well plates on glass coverslips.
The cells were transfected with 0.25 lg of GFP-arrestin 2 using
Lipofectamine 2000. For experiments using ED95/295, HEK293 cells
were transiently transfected with 0.25 lg of GFP-ED95/295 and 4 lg of
HA-tagged EP3 receptor cDNA. Studies with GFP-ED95/295 were
performed with a Nikon Eclipse TE300 ﬂuorescence microscope.
2.5. ELISA assay
HEK293 cells stably expressing EP3 isoforms were grown to con-
ﬂuence in 12-well plates. Cells were treated with 1 lM PGE2 or vehicle
at 37 C for various times. Reactions were stopped with ice cold 2%
PFA. Cells were washed, blocked with 1% BSA in PBS for 45 min and
incubated with anti-HA.11 monoclonal antibody at a 1:1000 dilution
for 30 min. Cells were blocked again for 15 min and incubated with
horseradish peroxidase-conjugated antibody at a 1:1000 dilution for 30
min. Cells were washed and exposed to substrate o-phenylenediamine
and hydrogen peroxide, to allow color development, and the reaction
terminated using sulfuric acid. Absorbance was measured using a
Perkin–Elmer microplate reader at 450 nm.3. Results
3.1. Immunoblotting of EP3 isoform transfected cells
The speciﬁcity of the HA-antibody with regard to the HA-
tagged isoforms was demonstrated by comparing immunoblots
of solubilized membranes from EP3 transfected HEK293 cells
with a blot from cells transfected with empty vector (mock
transfected). Samples were loaded into the gel to give 15 lg of
protein in each well. Fig. 1 shows that, whereas cells trans-
fected with the isoforms gave a band close to the predicted
molecular mass of the receptors (47 kDa), no band was ob-
served with mock transfected cells. Further, the blot demon-
strates that each of the isoforms is expressed at a similar level,
because the intensity of each band is similar.
Fig. 3. Agonist-induced internalization of EP3 receptor isoforms I, II,
and III. Cells expressing EP3.I, EP3.II or EP3.III were stimulated with
1 lM PGE2 for the indicated time periods. The amount of surface HA
immunoreactivity for each sample was measured by ELISA analysis.
Values are representatives of means S.E. of at least six independent
experiments, each done in triplicate. The amount of surface receptor is
expressed as a percentage of the sample not treated with agonist.
Fig. 2. Localization and traﬃcking of isoform, EP3.I. EP3.II, III, IV,
V, VI and f. HEK293 cells stably expressing HA-tagged EP3 receptor
isoforms were co-transfected with 0.25 lg GFP-arrestin. 48 h post-
transfection, cells were treated with vehicle ()) or 1 lM PGE2 (+) and
ﬁxed. The cells were then processed for simultaneous detection of
surface and internalized receptors and GFP-arrestin. For each isoform,
the left column shows the localization of each isoform, the middle
columns show the distribution of GFP-arrestin, and the right column
shows the superimposed image. Regions of overlap appear yellow.
Magniﬁcation 400·. Results were representatives of four separate
experiments.
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Several diﬀerent modes of agonist-induced internalization
are utilized by GPCRs. A common pathway, mediated by b-
arrestin, involves endocytosis into clathrin-coated pits. To
determine the mechanisms involved in internalization of EP3
isoforms, HEK293 cells expressing the isoforms were co-
transfected with b-arrestin 2 fused with GFP. Images obtained
with each isoform are presented in Fig. 2. Under basal con-
ditions (in the absence of PGE2), EP3.I was localized to the cell
surface and b-arrestin was dispersed throughout the cyto-
plasm. In the absence of agonist, all of the other isoforms were
primarily located on the cell surface. Of these, isoforms III, IV,
and f are located just below the cellular surface, whereas
isoform V is more centrally located in the intracellular
compartment. The speciﬁcity of the anti-HA antibody in im-
munoﬂuorescence studies was apparent from the observation
that mock transfected cells showed no ﬂuorescence following
treatment (not shown). In other experiments, we ﬁxed the cells
prior to labeling with the anti-HA antibody. No diﬀerence was
seen in the distribution of receptors under basal conditions,
indicating that the antibody itself does not cause endocytosis
(not shown).
When stimulated with PGE2, the EP3.I isoform translocated
to large, punctate vesicles below the cell surface and b-arrestin
migrated into the same vesicles. Isoforms II, V, VI, and f in-
ternalized to a lesser extent than EP3.I, whereas isoforms III
and IV did not internalize.
The distribution pattern of b-arrestin varied with each iso-
form and in each case was distinct from that observed with
EP3.I. Under basal conditions, EP3.II was present along the
cellular surface and the b-arrestin was dispersed throughout
the cytoplasm. When treated with PGE2, some of the receptor
internalized; however, the b-arrestin did not translocate with
the receptor. The experiments were performed four times with
diﬀerent clones of EP3.II. In each experiment, b-arrestin con-
sistently failed to colocalize with the receptor.
When the same experiment was performed on isoforms III
and IV, receptors that do not internalize, b-arrestin remained
dispersed throughout the cytoplasm.
Isoforms V and VI yielded similar results when co-expressed
with b-arrestin 2, probably due to their similar C-tail compo-
sition. Under basal conditions, both receptors were primarily
located on the cell surface, with a small amount of EP3.V in
the intracellular compartment. b-Arrestin was distributed
throughout the cytoplasm, except for an overlap with inter-
nalized EP3.V. When stimulated with PGE2, both isoforms
partially internalized to discrete areas of the cells and b-arr-
estin translocated with the internalized receptors.
Isoform f behaved mostly like isoform I. Under basal con-
ditions, the receptor was located on the cell surface and b-
arrestin was evenly distributed throughout the cytoplasm.
Upon agonist challenge, the two co-localized into endosomes.
3.3. ELISA analysis of internalization
To conﬁrm diﬀerences in the extent of internalization, we
used ELISA. We studied isoforms I, II and III because they
were representative of receptors that internalize robustly (iso-
form I), receptors that internalize to a lesser degree (isoforms
II, V, VI, and f), and receptors that fail to internalize at all
(isoforms III and IV). Cell-lines expressing each of the iso-
forms were challenged with PGE2 for 0–60 min and the
amount of remaining surface HA antigen was determined.EP3.I underwent rapid internalization to the extent of greater
than 60% (Fig. 3). These data correlate with the images of EP.I
obtained by confocal microscopy. EP3.II internalized to a
lesser degree and EP3.III did not internalize in ELISA analy-
sis, conﬁrming prior confocal results.
Fig. 4. Eﬀect of dominant negative Eps15 mutant GFP-ED95/295 on
endocytosis of isoforms EP3.I, EP3.II and EP3.f. HEK293 cells were
transiently transfected with HA-tagged EP3 receptor isoforms together
with GFP-ED95/295 cDNA. 48 h post-transfection, cells were treated
with vehicle ()) or 1 lM PGE2 (+) and ﬁxed. The cells were then
processed for simultaneous detection of surface and internalized re-
ceptors. As a control, the upper left group of images shows internali-
zation of EP3.I in the presence of GFP-arrestin. The upper right group
of images shows that GFP-ED95/295 prevents internalization of HA-
EP3.I. The lower left series of images show that GFP-ED95/295 has no
eﬀect on EP3.II internalization. The lower right series of images show
that GFP-ED95/295 inhibits internalization of EP3.f. Images were
obtained using a Nikon Eclipse TE300 ﬂuorescence microscope.
Magniﬁcation 400·. The experiments were repeated three times with
similar results.
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To further examine the mechanism of internalization, we co-
transfected HEK 293 cells with EP3.I and a dominant negative
mutant of Eps15. Eps15 (EGFR pathway substrate clone 15) is
a protein component of plasma membrane clathrin-coated pits
that is associated with AP-2 [15]. Overexpression of dominant
negative mutants of Eps15 has been shown to inhibit clathrin-
dependent endocytosis [15].
Fig. 4 compares the distribution of HA-EP3.I and GFP-
arrestin with dominant negative Eps15 mutant GFP-ED95/295
in transfected cells in the absence or presence of PGE2. Mi-
crographs presented in the upper left panels show that EP3.I
internalizes in the presence of PGE2 and co-localizes with b-
arrestin as described above. In contrast, ED95/295 prevented
PGE2-mediated internalization of EP3.I, indicating that EP3.I
endocytosis involves clathrin-coated pits. Fig. 4 also shows
that internalization of HA-EP3.II is not aﬀected by GFP-
ED95/295 (lower left series), whereas internalization of EP3.f is
abolished by GFP-ED95/295 (lower right series). The results
correlate with the observation in Fig. 2 that EP3.I and EP3.f
internalize in a b-arrestin-dependent manner, whereas EP3.II
internalizes independently of b-arrestin.4. Discussion
The diﬀerent C-tails of the EP3 receptor isoforms appear to
be involved in controlling receptor localization and traﬃcking.
Our ﬁndings are consistent with studies of other GPCRs.Membrane-targeting studies on the three mouse EP3 receptor
isoforms show that they diﬀer in subcellular localization de-
pending on their C-tails [14]. In fact, a truncated form of the
mouse EP3 isoforms was retained in the intracellular com-
partment, suggesting that it is the C-tail that directs targeting
of the receptors to the cell surface. Other studies have also
implicated the C-tail of GPCRs in receptor localization. The
a1 adrenergic receptor subtypes A, B, and D all showed dif-
ferences in cellular localization. Hence, subtype 1B was located
on the plasma membrane, subtype 1A was present both on the
plasma membrane and in the intracellular compartment, and
subtype 1D exhibited a perinuclear orientation [16].
All human EP3 isoforms were located primarily on the cell
surface under non-stimulated conditions. Isoforms III, IV, V,
and f were also present in the intracellular compartment, which
may be related to the fact that some of the isoforms are con-
stitutively active [12]. The a1D-adrenergic subtype is thought
to be localized intracellularly because it is constitutively active
and, therefore, constitutively internalized [12].
Upon PGE2 stimulation, EP3.I internalized rapidly and
robustly into punctate vesicles. Isoforms II, V, VI, and f also
internalized but to a lesser extent. Their internalization was
unusual in two ways. First, a large amount of receptor was
retained on the cell surface. Second, the internalized receptor
appeared to migrate laterally to one quadrant of the cells. It
may be that these isoforms are being downregulated and are
entering lysosomes or proteosomes.
Isoforms III and IV, the shortest isoforms, do not internalize
in response to agonist. Moreover, isoforms III and IV contain
no serine or threonine residues, which have been implicated in
internalization of other GPCRs including the m2 muscarininc
acetylcholine receptor [17], the chemokine CXCR4 receptor
[18] and the bradykinin B2 receptor [19].
Internalization frequently depends on the nature of the
carboxyl-tail and its relation to adaptor proteins such as b-
arrestin [20]. In general, carboxyl-tails with a signiﬁcant
number of serines and threonines may be phosphorylated, al-
lowing the binding of b-arrestin. b-Arrestin is crucial in the
regulation of GPCR traﬃcking and would be expected to co-
localize with an internalized receptor such that the two are
associated with a clathrin-coated pit.
Co-expression of EP3.I with b-arrestin showed that the in-
ternalized receptor and arrestin co-localize into the same en-
dosomes, indicating that this isoform is likely internalized via a
mechanism involving clathrin-coated pits. This conclusion is
conﬁrmed by the lack of internalization of EP3.I in the pres-
ence of the dominant negative mutant form of the clathrin
associated protein Eps15, ED95/295, which has been shown to
inhibit clathrin-coated pit assembly. Isoform EP3.f also ap-
pears to internalize by a b-arrestin, clathrin-dependent mech-
anism. By contrast, internalization of isoform EP3.II proceeds
independently of b-arrestin and is not aﬀected by ED95/295,
indicating that EP3.II may internalize by an alternate mecha-
nism. Isoforms V and VI both partially internalized to discrete
areas of the cells when stimulated with PGE2. However, only a
small fraction of b-arrestin co-migrated with the internalized
receptors. Upon stimulation with agonist, neither isoform III
nor IV internalized and b-arrestin remained throughout the
cell.
In summary, the isoforms of the human prostaglandin EP3
receptor show diﬀerent degrees of internalization in response to
PGE2. In addition, the isoforms appear to internalize by dif-
H.A. Bilson et al. / FEBS Letters 572 (2004) 271–275 275ferent mechanisms from one another. The ﬁndings may indicate
diﬀerences in physiological function among the isoforms, with
some responding rapidly to changes in PGE2 concentration and
others involved in prolonged responses to PGE2.
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